CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 558 enrolled
Drug / intervention
Atezolizumab +2 moredrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03434379
NCT03434379Phase 3Completed
CompareCT.gov

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Hoffmann-La Roche·interventional·Posted Feb 15, 2018·Updated Oct 23, 2023

In Brief

A Phase 3 clinical trial evaluating Atezolizumab, Bevacizumab, and 1 other intervention for Carcinoma, Hepatocellular. Completed, enrolled 558 participants across 119 sites in 17 countries.

Detailed Summary

This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular
CountriesAustralia, Canada, China, Czechia, France, Germany, Hong Kong, Italy, Japan, Poland, Russia, Singapore, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 15, 2018
Enrollment StartMar 15, 2018
Primary CompletionAug 31, 2020
Study CompletionNov 17, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.4 years ago

Interventions

Atezolizumabdrug

Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle

Bevacizumabdrug

Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle

Sorafenibdrug

Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle